Arbutus Biopharma Corporation – NASDAQ:ABUS
Arbutus Biopharma stock price today
$3.49
+0.28
+8.72%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 6 hours
Arbutus Biopharma stock price monthly change
-10.59%
month
Arbutus Biopharma stock price quarterly change
-10.59%
quarter
Arbutus Biopharma stock price yearly change
+29.43%
year
Arbutus Biopharma key metrics
Market Cap | 605.42M |
Enterprise value | 410.64M |
P/E | -6.33 |
EV/Sales | 10.52 |
EV/EBITDA | -6.63 |
Price/Sales | 11.25 |
Price/Book | 3.20 |
PEG ratio | -0.14 |
EPS | -0.43 |
Revenue | 12.98M |
EBITDA | -77.76M |
Income | -74.38M |
Revenue Q/Q | -77.08% |
Revenue Y/Y | -60.79% |
Profit margin | -178.01% |
Oper. margin | -162.03% |
Gross margin | 0% |
EBIT margin | -162.03% |
EBITDA margin | -598.84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArbutus Biopharma stock price history
Arbutus Biopharma stock forecast
Arbutus Biopharma financial statements
| Jun 2023 | 4.65M | -17.09M | -367.53% |
|---|---|---|---|
| Sep 2023 | 4.65M | -20.10M | -431.6% |
| Dec 2023 | 2.14M | -19.31M | -900.33% |
| Mar 2024 | 1.53M | -17.87M | -1166.78% |
| Mar 2024 | 1.53M | -17.87M | -1166.78% |
|---|---|---|---|
| Sep 2025 | 2.12M | -23.58M | -1111% |
| Oct 2025 | 1.54M | -17.56M | -1137.47% |
| Dec 2025 | 1.01M | -17.56M | -1737.72% |
Analysts Price target
Financials & Ratios estimates
| 2024-02-29 | -0.12 | -0.12 |
|---|
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 7.02% |
|---|---|
| 2020 | 4.5% |
| 2021 | 2.94% |
| 2022 | |
| 2023 |
| Jun 2023 | 176823000 | 42.13M | 23.83% |
|---|---|---|---|
| Sep 2023 | 158641000 | 39.30M | 24.78% |
| Dec 2023 | 144401000 | 38.38M | 26.58% |
| Mar 2024 | 150290000 | 35.65M | 23.72% |
| Jun 2023 | -19.55M | 1.44M | 4.74M |
|---|---|---|---|
| Sep 2023 | -21.78M | 10.42M | 1.68M |
| Dec 2023 | -16.22M | 21.64M | 3.41M |
| Mar 2024 | -19.29M | 11.69M | 24.43M |
Arbutus Biopharma alternative data
| Aug 2023 | 96 |
|---|---|
| Sep 2023 | 96 |
| Oct 2023 | 96 |
| Nov 2023 | 96 |
| Dec 2023 | 96 |
| Jan 2024 | 96 |
| Feb 2024 | 96 |
| Mar 2024 | 73 |
| Apr 2024 | 73 |
| May 2024 | 73 |
| Jun 2024 | 73 |
| Jul 2024 | 73 |
Arbutus Biopharma other data
35.86%
+4.58%
of ABUS is owned by hedge funds
108
-12
54.14M
+7.61M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 34097 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SIMS KAREN officer: Chief Medical Officer | Common Shares | 4,358 | $2.31 | $10,080 | ||
Sale | HASTINGS DAVID C officer: Chief Financial Officer | Common Shares | 9,593 | $2.31 | $22,189 | ||
Sale | SOFIA MICHAEL J. officer: Chief Sc.. | Common Shares | 9,982 | $2.31 | $23,088 | ||
Sale | MCELHAUGH MICHAEL J. director, officer.. | Common Shares | 10,164 | $2.31 | $23,509 | ||
Sale | SOFIA MICHAEL J. officer: Chief Sc.. | Common Shares | 200,000 | $5.09 | $1,018,000 | ||
Sale | MCELHAUGH MICHAEL J. officer: Chief Bu.. | Common Stock | 20,000 | $5 | $100,000 | ||
Sale | MCELHAUGH MICHAEL J. officer: Chief Bu.. | Common Stock | 40,000 | $5 | $200,080 | ||
Sale | MCELHAUGH MICHAEL J. officer: Chief Bu.. | Common Stock | 40,000 | $5 | $200,080 | ||
Sale | MCELHAUGH MICHAEL J. officer: Chief Bu.. | Common Stock | 20,000 | $5.01 | $100,200 | ||
Option | MURRAY MARK J. director, officer: President an.. | Employee Stock Option (Right to Buy) | 25,000 | $1.35 | $33,750 |
| Patent |
|---|
Grant Filling date: 22 Aug 2018 Issue date: 20 Sep 2022 |
Grant Utility: Targeted compositions Filling date: 10 Apr 2018 Issue date: 30 Aug 2022 |
Application Filling date: 31 May 2018 Issue date: 25 Aug 2022 |
Grant Utility: Lipid containing formulations Filling date: 13 Dec 2019 Issue date: 23 Aug 2022 |
Grant Filling date: 30 Jan 2020 Issue date: 26 Jul 2022 |
Grant Filling date: 20 Dec 2017 Issue date: 7 Jun 2022 |
Application Filling date: 19 Mar 2020 Issue date: 2 Jun 2022 |
Application Filling date: 1 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 8 Nov 2019 Issue date: 5 May 2022 |
Grant Filling date: 25 May 2021 Issue date: 3 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Moderna Investors Should Beware Patent-Dispute Fallout
Roivant Sciences: Risk-Transforming Deal Met With Crickets
BioNTech: Able To Tap Into High Medical Need PD-L1 Refractory NSCLC Market
Arbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023
Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
Biopharmaceutical Stocks Continue To Perform Well, With Many Attractive Values Remaining
Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
-
What's the price of Arbutus Biopharma stock today?
One share of Arbutus Biopharma stock can currently be purchased for approximately $3.49.
-
When is Arbutus Biopharma's next earnings date?
Unfortunately, Arbutus Biopharma's (ABUS) next earnings date is currently unknown.
-
Does Arbutus Biopharma pay dividends?
No, Arbutus Biopharma does not pay dividends.
-
How much money does Arbutus Biopharma make?
Arbutus Biopharma has a market capitalization of 605.42M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 53.51% to 18.14M US dollars. Arbutus Biopharma made a loss 72.85M US dollars in net income (profit) last year or -$0.12 on an earnings per share basis.
-
What is Arbutus Biopharma's stock symbol?
Arbutus Biopharma Corporation is traded on the NASDAQ under the ticker symbol "ABUS".
-
What is Arbutus Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Arbutus Biopharma?
Shares of Arbutus Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the following people:
- Mr. William H. Collier Pres, Chief Executive Officer & Director(age: 65, pay: $972,320)
- Dr. Michael J. Sofia Ph.D. Chief Scientific Officer(age: 67, pay: $637,750)
- Mr. Michael J. McElhaugh Chief Bus. Officer(age: 51, pay: $603,420)
-
How many employees does Arbutus Biopharma have?
As Jul 2024, Arbutus Biopharma employs 73 workers.
-
When Arbutus Biopharma went public?
Arbutus Biopharma Corporation is publicly traded company for more then 18 years since IPO on 26 Jul 2007.
-
What is Arbutus Biopharma's official website?
The official website for Arbutus Biopharma is arbutusbio.com.
-
Where are Arbutus Biopharma's headquarters?
Arbutus Biopharma is headquartered at 701 Veterans Circle, Warminster, PA.
-
How can i contact Arbutus Biopharma?
Arbutus Biopharma's mailing address is 701 Veterans Circle, Warminster, PA and company can be reached via phone at +267 469 0914.
Arbutus Biopharma company profile:
Arbutus Biopharma Corporation
arbutusbio.comExchange:
NASDAQ
Full time employees:
73
Industry:
Biotechnology
Sector:
Healthcare
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
701 Veterans Circle
Warminster, PA 18974
Warminster, PA 18974
CIK: 0001447028
ISIN: CA03879J1003
CUSIP: 03879J100
